Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Microtubule Inhibitor [EPC]
Docetaxel Anhydrous is a potent antineoplastic agent in the taxane class, functioning as a microtubule inhibitor to treat various cancers, including breast, lung, and prostate malignancies.
Name
Docetaxel Anhydrous
Raw Name
DOCETAXEL ANHYDROUS
Category
Microtubule Inhibitor [EPC]
Drug Count
3
Variant Count
36
Last Verified
February 17, 2026
RxCUI
1093280, 1860619, 1860480, 1860485, 2697044, 2728902, 2054168, 2054170, 2723663, 2723664, 2723665, 2723666, 1861411, 1001405
UNII
699121PHCA
About Docetaxel Anhydrous
Docetaxel Anhydrous is a potent antineoplastic agent in the taxane class, functioning as a microtubule inhibitor to treat various cancers, including breast, lung, and prostate malignancies.
Detailed information about Docetaxel Anhydrous
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Docetaxel Anhydrous.
Historically, docetaxel was developed following the success of paclitaxel. While paclitaxel was originally derived from the bark of the Pacific yew tree (Taxus brevifolia), docetaxel is synthesized using a precursor extracted from the needles of the European yew tree (Taxus baccata). The FDA first approved docetaxel (under the brand name Taxotere) in 1996, and since then, it has become a cornerstone of oncological pharmacology. It is primarily used to treat breast cancer, non-small cell lung cancer (NSCLC), hormone-refractory prostate cancer, gastric (stomach) adenocarcinoma, and squamous cell carcinoma of the head and neck.
At the molecular level, Docetaxel Anhydrous acts as a 'microtubule stabilizer.' To understand this, one must look at how cells divide. Microtubules are protein structures within the cell that act like a scaffolding or a railway system. During mitosis (cell division), these microtubules must constantly assemble and disassemble to move chromosomes into the two new daughter cells.
Docetaxel binds to the beta-tubulin subunit of the microtubules with high affinity. Unlike other chemotherapy drugs like vinca alkaloids (which prevent microtubules from forming), docetaxel promotes the assembly of microtubules from tubulin dimers but, crucially, inhibits their disassembly. This leads to the formation of stable, non-functional microtubule bundles within the cell. Because the microtubules cannot 'unlock' or break down, the cell becomes stuck in the G2 and M phases of the cell cycle. Unable to complete division, the cancer cell eventually undergoes apoptosis (programmed cell death). This mechanism is particularly effective against rapidly dividing cancer cells, though it also affects some healthy cells, leading to the drug's characteristic side effect profile.
The movement of Docetaxel Anhydrous through the body follows a complex three-compartment model. Understanding these kinetics helps healthcare providers manage dosing intervals and predict potential toxicities.
Docetaxel Anhydrous is FDA-approved for several high-stakes oncological indications. Healthcare providers typically utilize it in the following contexts:
Docetaxel Anhydrous is available exclusively as an injection. It is typically supplied as:
> Important: Only your healthcare provider can determine if Docetaxel Anhydrous is right for your specific condition. The choice of chemotherapy is based on the stage of cancer, genetic markers, and your overall health status.
Dosage for Docetaxel Anhydrous is highly individualized and is calculated based on Body Surface Area (BSA), measured in milligrams per square meter (mg/m²). Healthcare providers will calculate your BSA using your height and weight before every cycle.
Docetaxel Anhydrous is not currently FDA-approved for use in pediatric patients. The safety and effectiveness in children have not been established. While some clinical trials have explored its use in specific pediatric solid tumors, it is not considered a standard treatment in this population.
Because docetaxel is primarily cleared by the liver, mild to moderate kidney dysfunction does not typically require a dose adjustment. However, healthcare providers will monitor kidney function (creatinine levels) to ensure the body can handle the overall fluid load associated with the infusion.
Hepatic (liver) impairment is a critical contraindication for high-dose docetaxel. Patients with elevated bilirubin or significantly high liver enzymes (ALT/AST > 1.5 times the upper limit of normal) are at a much higher risk of severe toxicity and death. In such cases, the dose may be reduced to 75 mg/m² or the treatment may be withheld entirely.
Patients over the age of 65 may be more sensitive to the side effects of Docetaxel Anhydrous, particularly the risk of infection (neutropenia) and severe diarrhea. Clinical trials have shown that elderly patients in the TAX 327 prostate cancer trial had a higher incidence of anemia and infection compared to younger patients. Dose reductions or longer intervals between treatments may be considered by the oncology team.
Docetaxel Anhydrous is administered as an intravenous infusion in a clinical setting (hospital or infusion center).
Since this medication is administered by healthcare professionals on a strict schedule, a 'missed dose' usually refers to a delayed appointment. If you cannot attend your scheduled infusion, contact your oncology clinic immediately. Delaying chemotherapy can affect the efficacy of the treatment, but the schedule can be adjusted by your doctor.
An overdose of Docetaxel Anhydrous is rare because it is administered by trained medical staff. However, if an error occurs, the primary complications would be a severe drop in white blood cells (bone marrow suppression), intense inflammation of the mucous membranes (mucositis), and severe peripheral neuropathy (numbness/tingling). There is no specific antidote for docetaxel. Treatment involves supportive care, such as G-CSF (growth factors) to boost white blood cells and intensive monitoring of vital organs.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip premedication without medical guidance, as this significantly increases the risk of life-threatening infusion reactions.
Docetaxel Anhydrous is a potent medication, and most patients will experience some level of side effects. These are generally manageable with supportive care.
> Warning: Stop taking Docetaxel Anhydrous and call your doctor immediately or seek emergency care if you experience any of the following:
Some effects of Docetaxel Anhydrous may persist long after the final dose. Peripheral Neuropathy (numbness, tingling, or burning in the hands and feet) can sometimes be permanent or take years to resolve. Permanent Alopecia (hair loss) has been documented in a small percentage of breast cancer survivors. Additionally, Amenorrhea (cessation of menstrual periods) may occur, which can lead to early menopause in women.
The FDA has issued several 'Black Box Warnings' for Docetaxel Anhydrous, the highest level of caution for a medication:
Report any unusual symptoms to your healthcare provider immediately. Early intervention is key to managing chemotherapy toxicity.
Docetaxel Anhydrous is a high-alert medication that requires careful monitoring by an oncology specialist. Patients must be aware that this drug can significantly suppress the immune system, making common infections potentially fatal. It is also vital to adhere to the premedication schedule (usually dexamethasone) to prevent severe infusion reactions and fluid retention.
According to the FDA-approved labeling, Docetaxel Anhydrous carries several critical warnings:
To ensure safety, your healthcare team will require regular testing:
Because of the potential for allergic reaction symptoms, the alcohol content in the infusion, and the fatigue associated with chemotherapy, patients are advised not to drive themselves home after their first few treatments. Once you know how the medication affects you, discuss driving with your doctor.
Patients should limit alcohol consumption while on Docetaxel Anhydrous. Alcohol can strain the liver, which is already working hard to process the chemotherapy, and may worsen the 'intoxication' feeling caused by the ethanol in the drug formulation.
Chemotherapy is usually discontinued if the cancer progresses, if toxicities become unmanageable (e.g., Grade 3 or 4 neuropathy), or if the patient completes the prescribed number of cycles. There is no 'withdrawal syndrome' like those seen with antidepressants or opioids, but the side effects (like low blood counts) can persist for weeks after the last dose.
> Important: Discuss all your medical conditions, especially liver disease or previous allergic reactions to drugs like polysorbate 80, with your healthcare provider before starting Docetaxel Anhydrous.
While few drugs are strictly contraindicated, the use of live vaccines (such as the yellow fever vaccine or the intranasal flu vaccine) is highly dangerous while on Docetaxel Anhydrous. Because the drug suppresses the immune system, a live vaccine could cause a full-blown, life-threatening infection.
Docetaxel Anhydrous does not typically interfere with the chemical reactions of lab tests, but its biological effects will certainly change the results of:
For each major interaction, the management strategy usually involves either avoiding the interacting drug or reducing the docetaxel dose by approximately 50% if a strong inhibitor must be used.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and vitamins.
There are specific scenarios where Docetaxel Anhydrous must NEVER be used because the risks far outweigh any potential benefits:
Conditions requiring careful risk-benefit analysis include:
Patients who have had allergic reactions to Paclitaxel (Taxol) or Cabazitaxel (Jevtana) may have a cross-sensitivity to Docetaxel Anhydrous. While they are not identical, their similar chemical structures mean the immune system may react to both. In such cases, the oncology team may perform a 'desensitization' protocol or choose a different class of chemotherapy.
> Important: Your healthcare provider will evaluate your complete medical history, including liver health and previous drug allergies, before prescribing Docetaxel Anhydrous.
Docetaxel Anhydrous is considered highly teratogenic (causes birth defects). According to the FDA, it is classified in a category indicating positive evidence of human fetal risk.
It is not known if docetaxel passes into human breast milk. However, because of the potential for serious adverse reactions in nursing infants (including immune suppression and growth issues), breastfeeding is strictly discouraged during treatment and for at least one week after the last dose.
As noted, Docetaxel Anhydrous is not approved for children. Clinical studies in pediatric populations have not demonstrated sufficient efficacy to justify the toxicity profile in standard pediatric cancers. Growth effects in children have not been formally studied but are expected to be significant given the drug's mechanism of inhibiting cell division.
Patients 65 years and older are at a higher risk for several complications:
While docetaxel is not primarily cleared by the kidneys, the overall physiological stress of the drug and the required fluid volumes mean that patients with a GFR (Glomerular Filtration Rate) below 30 mL/min should be monitored closely for electrolyte imbalances.
This is the most critical special population for Docetaxel Anhydrous. The drug's clearance is directly tied to liver health.
> Important: Special populations require individualized medical assessment and often involve a multidisciplinary team of specialists.
Docetaxel Anhydrous is a cytotoxic antineoplastic agent that acts by disrupting the microtubular network in cells. It binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously preventing their disassembly. This leads to the production of microtubule bundles without normal function. The stabilization of microtubules inhibits the reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Specifically, it induces a 'mitotic block' at the G2/M phase of the cell cycle, eventually triggering the apoptotic cascade through the activation of caspase-3 and caspase-9.
The pharmacodynamics of docetaxel are characterized by a steep dose-response relationship regarding both tumor shrinkage and bone marrow toxicity. The onset of action is immediate upon infusion, but the clinical effect on tumor size is typically not measurable until after 2 or 3 cycles (6-9 weeks). Tolerance to the drug does not typically develop, but cumulative toxicity (especially fluid retention and neuropathy) often limits the total number of cycles a patient can receive.
| Parameter | Value |
|---|---|
| Bioavailability | 100% (Intravenous) |
| Protein Binding | 94% - 97% (Albumin, Alpha-1-acid glycoprotein) |
| Half-life | 11.1 hours (Terminal phase) |
| Tmax | End of 1-hour infusion |
| Metabolism | Hepatic (Primarily CYP3A4) |
| Excretion | Fecal (75%), Renal (<6%) |
Docetaxel Anhydrous is part of the Taxane class of drugs. Other medications in this class include Paclitaxel (Taxol) and Cabazitaxel (Jevtana). While they share a similar mechanism, docetaxel is generally considered more potent on a molar basis than paclitaxel and has a slightly different spectrum of activity and side effect profile (e.g., more fluid retention but less frequent neuropathy compared to some paclitaxel formulations).
Medications containing this ingredient
Common questions about Docetaxel Anhydrous
Docetaxel Anhydrous is a chemotherapy medication used to treat several types of advanced or metastatic cancers. It is FDA-approved for breast cancer, non-small cell lung cancer, advanced prostate cancer, stomach cancer, and head and neck cancer. It works by stopping cancer cells from dividing, which eventually causes them to die. Healthcare providers often use it when other treatments have failed or as part of a combination therapy. It is administered as an intravenous infusion in a clinical setting.
The most common side effects include a significant drop in white blood cells (neutropenia), which increases infection risk, and hair loss (alopecia) on the scalp and body. Many patients also experience fluid retention, which causes swelling in the legs or weight gain. Other frequent issues include fatigue, nausea, diarrhea, and changes in the fingernails or toenails. Some patients also report a metallic taste in their mouth or 'pins and needles' sensations in their hands and feet. Most of these are managed with additional medications provided by your oncology team.
It is generally advised to avoid or strictly limit alcohol while undergoing treatment with Docetaxel Anhydrous. The medication itself is often formulated with ethanol (alcohol), which can make you feel intoxicated or drowsy during and after the infusion. Additionally, alcohol can put extra strain on the liver, which is the primary organ responsible for breaking down the chemotherapy. Drinking alcohol could also worsen certain side effects like nausea or dehydration. Always check with your doctor before consuming any alcohol during your treatment cycle.
No, Docetaxel Anhydrous is not safe for use during pregnancy as it can cause severe harm or death to an unborn baby. It is a potent drug that interferes with cell division, a process that is vital for fetal development. Women of childbearing age must use highly effective birth control during treatment and for several months afterward. Men should also use contraception to avoid fathering a child during treatment, as the drug can affect sperm. If you become pregnant while receiving this medication, you must notify your doctor immediately.
While Docetaxel Anhydrous begins working at the cellular level immediately after the infusion starts, visible results are not instant. Most oncologists will wait until you have completed 2 or 3 cycles (about 6 to 9 weeks) before performing a CT scan or MRI to see if the tumor has shrunk. Some patients may notice an improvement in symptoms, such as reduced pain or better breathing, earlier than that. The effectiveness is monitored through these scans and blood tests for tumor markers. Your doctor will discuss the progress with you after each evaluation.
Since Docetaxel Anhydrous is administered by a doctor in a clinic, 'stopping' it means deciding not to go to your next scheduled appointment. You should never stop your treatment without a detailed discussion with your oncologist. Stopping chemotherapy early can allow the cancer to grow or become resistant to the drug. However, if you are experiencing severe side effects, your doctor may decide to delay a dose, reduce the amount you receive, or stop the treatment altogether. This is a medical decision based on your safety and the treatment's goals.
If you miss an appointment for your Docetaxel Anhydrous infusion, call your oncology clinic as soon as possible to reschedule. Chemotherapy is most effective when given on a precise schedule to catch cancer cells at specific points in their growth cycle. While a delay of a few days is sometimes necessary for safety (such as if your blood counts are too low), unnecessary delays should be avoided. Your healthcare team will work with you to get your treatment back on track. They will also advise you on any changes needed for your premedication schedule.
Weight gain during docetaxel treatment is often not from fat, but from a side effect called fluid retention. This medication can cause the body to hold onto extra water, leading to swelling in the ankles, legs, and sometimes the abdomen. This can result in a rapid increase in weight over a few days. It is important to monitor your weight and report an increase of more than 3-5 pounds in a week to your doctor. They may prescribe diuretics or adjust your steroid premedication to help manage this fluid buildup.
Docetaxel Anhydrous has many potential drug interactions, especially with medications that affect liver enzymes like CYP3A4. This includes certain antibiotics, antifungals, and even herbal supplements like St. John's Wort. Some of these interactions can make the chemotherapy much more toxic, while others can make it less effective. You must provide your oncologist with a complete list of all prescriptions, over-the-counter drugs, and vitamins you are taking. They will check for 'contraindicated' combinations and may adjust your medications to ensure your safety during chemotherapy.
Yes, Docetaxel Anhydrous is available as a generic medication. The original brand-name version, Taxotere, was the first to be approved, but several manufacturers now produce generic docetaxel injections. Generic versions are required by the FDA to have the same active ingredient, strength, and dosage form as the brand name. Using a generic can often reduce the cost of cancer treatment for patients and insurance providers. Your hospital or infusion center will likely use the version that is currently available in their pharmacy, which may be the generic form.